[go: up one dir, main page]

WO2005023291A3 - Use of glp1-agonists in the treatment of patients with type i diabetes - Google Patents

Use of glp1-agonists in the treatment of patients with type i diabetes Download PDF

Info

Publication number
WO2005023291A3
WO2005023291A3 PCT/DK2004/000599 DK2004000599W WO2005023291A3 WO 2005023291 A3 WO2005023291 A3 WO 2005023291A3 DK 2004000599 W DK2004000599 W DK 2004000599W WO 2005023291 A3 WO2005023291 A3 WO 2005023291A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
type
patients
treatment
glp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2004/000599
Other languages
French (fr)
Other versions
WO2005023291A2 (en
Inventor
Lars Hansen
Henrik Bindesboel Mortensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of WO2005023291A2 publication Critical patent/WO2005023291A2/en
Publication of WO2005023291A3 publication Critical patent/WO2005023291A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to the use of GLP-1 agonists in the treatment of patients with type I diabetes, where the patient is newly diagnosed with type 1 diabetes when treatment with the GLP-1 agonist is initiated. The present invention also relates to the use of GLP-1 agonists to prolong the remission period in such patients. The present invention further re-lates to a diagnostic test which utilizes measurement of endogenous GLP-1 levels to predict loss of beta cell function in patients with type I diabetes. The present invention further relates to methods for determining whether a patient with type 1 diabetes is in need of treatment with a GLP-1 agonist and/or is in remission.
PCT/DK2004/000599 2003-09-11 2004-09-10 Use of glp1-agonists in the treatment of patients with type i diabetes Ceased WO2005023291A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200301321 2003-09-11
DKPA200301321 2003-09-11
US50550003P 2003-09-24 2003-09-24
US60/505,500 2003-09-24

Publications (2)

Publication Number Publication Date
WO2005023291A2 WO2005023291A2 (en) 2005-03-17
WO2005023291A3 true WO2005023291A3 (en) 2005-04-28

Family

ID=34276709

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2004/000599 Ceased WO2005023291A2 (en) 2003-09-11 2004-09-10 Use of glp1-agonists in the treatment of patients with type i diabetes

Country Status (1)

Country Link
WO (1) WO2005023291A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
US11612640B2 (en) 2018-04-19 2023-03-28 Sciwind Biosciences Co., Ltd. Acylated GLP-1 derivative

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007012188A1 (en) 2005-07-27 2007-02-01 Qinghua Wang GLP/1/EXENDM 4 IgG Fc FUSION CONSTRUCTS FOR TREATMENT OF DIABETES
JP2009535380A (en) * 2006-05-02 2009-10-01 アクトジェニックス・エヌブイ Microbial intestinal delivery of obesity-related peptides
LT3228320T (en) 2008-10-17 2020-03-10 Sanofi-Aventis Deutschland Gmbh BETWEEN INSULIN AND GLP-1 AGONIST
KR101772372B1 (en) 2009-11-13 2017-08-29 사노피-아벤티스 도이칠란트 게엠베하 Pharmaceutical composition comprising a glp-1 agonist and methionine
PE20121362A1 (en) 2009-11-13 2012-10-17 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION INCLUDING DESPRO36EXENDIN-4 (1-39) -LYS6-NH2, INSULIN GLY (A21) -ARG (B31) -ARG (B32) AND METHIONINE
EP2611458B1 (en) 2010-08-30 2016-09-21 Sanofi-Aventis Deutschland GmbH Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
ES2610362T3 (en) 2011-01-25 2017-04-27 Viviabiotech, S.L. 1,2,4-Oxadiazole derivatives as receptor modulating drugs for the glp-1 peptide
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PT3139948T (en) * 2014-05-07 2020-05-22 Novo Nordisk As Treatment of diabetes type 1 using glp-1 and anti-il-21
SI3139948T1 (en) * 2014-05-07 2020-07-31 Novo Nordisk A/S Treatment of diabetes type 1 using glp-1 and anti-il-21
HRP20230470T1 (en) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
CA3138387A1 (en) * 2019-05-02 2020-11-05 Closed Loop Medicine Ltd Methods and systems for providing personalised medicine to a patient
US12420014B2 (en) 2023-06-05 2025-09-23 Closed Loop Medicine Ltd. Dosing of incretin pathway drugs

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0201187A1 (en) * 1985-03-29 1986-11-12 Novo Nordisk A/S Determination of glycated (glycosylated) hemoglobin in blood
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
WO1995031214A1 (en) * 1994-05-12 1995-11-23 London Health Association Treatment of diabetes
WO1998008871A1 (en) * 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-1 derivatives
WO2000042026A1 (en) * 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
WO2003002136A2 (en) * 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
WO2004050115A2 (en) * 2002-12-03 2004-06-17 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0201187A1 (en) * 1985-03-29 1986-11-12 Novo Nordisk A/S Determination of glycated (glycosylated) hemoglobin in blood
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
WO1995031214A1 (en) * 1994-05-12 1995-11-23 London Health Association Treatment of diabetes
WO1998008871A1 (en) * 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-1 derivatives
WO2000042026A1 (en) * 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
WO2003002136A2 (en) * 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
WO2004050115A2 (en) * 2002-12-03 2004-06-17 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DANNE T ET AL: "Persistent differences among centers over 3 years in glycemic control and hypoglycemia in a study of 3,805 children and adolescents with type 1 diabetes from the Hvidore Study Group.", DIABETES CARE. AUG 2001, vol. 24, no. 8, August 2001 (2001-08-01), pages 1342 - 1347, XP002319817, ISSN: 0149-5992 *
HOEY H ET AL: "Good metabolic control is associated with better quality of life in 2,101 adolescents with type 1 diabetes.", DIABETES CARE. NOV 2001, vol. 24, no. 11, November 2001 (2001-11-01), pages 1923 - 1928, XP002319818, ISSN: 0149-5992 *
NORDLY S ET AL: "Quality of diabetes management in children and adolescents in Denmark.", DIABETIC MEDICINE : A JOURNAL OF THE BRITISH DIABETIC ASSOCIATION. JUL 2003, vol. 20, no. 7, July 2003 (2003-07-01), pages 568 - 574, XP002319819, ISSN: 0742-3071 *
OLSEN BIRTHE SUSSANE ET AL: "A 6-year nationwide cohort study of glycaemic control in young people with Type 1 diabetes: Risk markers for the development of retinopathy, nephropathy, and neuropathy", JOURNAL OF DIABETES AND ITS COMPLICATIONS, vol. 14, no. 6, November 2000 (2000-11-01), pages 295 - 300, XP002319816, ISSN: 1056-8727 *
VILSBOELL T ET AL: "EVALUATION OF BETA-CELL SECRETORY CAPACITY USING GLUCAGON-LIKE PEPTIDE 1", DIABETES CARE, AMERICAN DIABETES ASSOCIATION, ALEXANDRIA, VA, US, vol. 23, no. 6, June 2000 (2000-06-01), pages 807 - 812, XP000984497, ISSN: 0149-5992 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US11612640B2 (en) 2018-04-19 2023-03-28 Sciwind Biosciences Co., Ltd. Acylated GLP-1 derivative
US12508300B2 (en) 2018-04-19 2025-12-30 Sciwind Biosciences Co., Ltd Acylated GLP-1 derivative

Also Published As

Publication number Publication date
WO2005023291A2 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
WO2005023291A3 (en) Use of glp1-agonists in the treatment of patients with type i diabetes
Blüher et al. Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or Type II diabetes
Kwong et al. Imprecision of urinary iothalamate clearance as a gold-standard measure of GFR decreases the diagnostic accuracy of kidney function estimating equations
Kuwa et al. Relationships of glucose concentrations in capillary whole blood, venous whole blood and venous plasma
Barden et al. Association between the endothelin-1 gene Lys198Asn polymorphism blood pressure and plasma endothelin-1 levels in normal and pre-eclamptic pregnancy
EP3712279B1 (en) Methods for diagnosing and evaluating non-alcoholic steatohepatitis
Burkhardt et al. Creatinine clearance, Cockcroft-Gault formula and cystatin C: estimators of true glomerular filtration rate in the elderly?
TW200745543A (en) System and methods for providing corrected analyte concentration measurements
Hannon et al. Use of markers of dyslipidemia to identify overweight youth with insulin resistance
SE9401351D0 (en) A method of diagnosis
WO2008005814A3 (en) Method and apparatus for diagnosing pre-eclampsia
ATE438860T1 (en) P1GF AND FLT-1 AS PROGNOSTIC PARAMETERS IN CARDIOVASCULAR DISEASES
Ozder A novel indicator predicts 2019 novel coronavirus infection in subjects with diabetes
Ito et al. Importance of OGTT for diagnosing diabetes mellitus based on prevalence and incidence of retinopathy
Galderisi et al. Is insulin action a determinant of left ventricular relaxation in uncomplicated essential hypertension?
Yılmaz Agladioglu et al. Urinary C-peptide/creatinine ratio can distinguish maturity-onset diabetes of the young from type 1 diabetes in children and adolescents: a single-center experience
Kulkarni et al. Urinary C-Peptide and urine C-pentide/Creatinine ratio (UCPCR) are possible predictors of endogenous insulin secretion in T2DM subjects-a randomized study.
Demir et al. Evaluation of neutrophil gelatinase-associated lipocalin in normoalbuminuric normotensive type 1 diabetic adolescents.
EP1432731A4 (en) DIAGNOSIS AND CONTROL OF LUPUS ERYTHEMATEUX SYSTEMATIQUE AND SCLERODERMIE
Annane et al. Clinical equipoise remains for issues of adrenocorticotropic hormone administration, cortisol testing, and therapeutic use of hydrocortisone
Palatini et al. Cystatin C as predictor of microalbuminuria in the early stage of hypertension
Mott et al. Practice patterns in screening for metabolic disease in women with PCOS of diverse race-ethnic backgrounds
Arrendale et al. Assessment of glycated hemoglobin using A1CNow™ point-of-care device as compared to central laboratory testing
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
Graci et al. The intravenous insulin tolerance test is an accurate method for screening a general population for insulin resistance and related abnormalities

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase